focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSeneca Growth Regulatory News (HYG)

Share Price Information for Seneca Growth (HYG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 13.50
Bid: 10.00
Ask: 17.00
Change: 0.00 (0.00%)
Spread: 7.00 (70.00%)
Open: 13.50
High: 13.50
Low: 13.50
Prev. Close: 13.50
HYG Live PriceLast checked at -
Seneca Growth Capital VCT is an Investment Trust

To provide shareholders with an attractive income and capital return by investing its funds in a portfolio of both unquoted and quoted UK MedTech companies which meet the relevant criteria under the VCT Rules.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Net Asset Value(s)

4 Apr 2024 07:00

Net Asset Value(s)

Net Asset Value(s)

Seneca Growth Capital VCT Plc (the "Company")

4 April 2024

Net asset value (“NAV”)

The Directors and the Investment Manager of the Company, Seneca Partners Limited (“Seneca”), have reviewed the valuation of the Company’s Ordinary and B share investment portfolios and announce an updated NAV for each of the share classes as at 31 March 2024.

B Shares

As at 31 March 2024, the unaudited NAV per B share was 63.7p.

This is a decrease of 7.0p from the audited NAV as at 31 December 2023 of 70.7p, predominantly as a result of AIM market volatility. The B share NAV as at 31 March 2024 incorporates changes in the bid prices of the B share pool’s AIM/AQSE quoted investments combined with the impact of income receivable and running costs incurred in the period. There have been no material changes in the valuations of any of the unlisted investments during the period from 31 December 2023 to the date of this announcement.

The unaudited NAV total return per B share (NAV plus cumulative dividends) as at 31 March 2024 was 78.7p.

Ordinary Shares

As at 31 March 2024, the unaudited NAV of an Ordinary share was 16.8p per share.

This is a decrease of 1.7p from the audited NAV as at 31 December 2023 of 18.5p and is principally due to a reduction in the value of the Ordinary share pool’s investment in AIM quoted Scancell Holdings Plc and a decrease in the Ordinary share pool’s investment in AIM quoted Arecor Therapeutics Plc. As at 31 March 2024, shares in Scancell Holdings Plc were valued at 10.0p per share (31 December 2023: 10.5p) and shares in Arecor Therapeutics Plc were valued at 135.0p per share (31 December 2023: 180p). The Directors also reviewed the unquoted investments held in the Ordinary share portfolio and concluded that no changes were required to the carrying value of those investments.

The unaudited NAV total return per Ordinary share (NAV plus cumulative dividends) as at 31 March 2024 was 90.1p.

The change in NAV for both the B Shares and Ordinary Shares represents a decrease of 0.1p per share, respectively, on the unaudited NAVs as at 20 March 2024, announced on 22 March 2024 and which was included in the Supplementary Prospectus published by the Company on 28 March 2024.

For the purposes of calculating the unaudited net asset value per share for both share classes, quoted investments are carried at closing bid prices as at 31 March 2024 and unquoted investments are carried at fair value as at 31 March 2024.

The number of B shares in issue at 31 March 2024 was 21,780,329 and the number of Ordinary shares was 8,115,376. Therefore, the total number of voting rights in the Company is 29,895,705.

The B share Offer by the Company remains open for the 2023/24 tax year until midday today, 4 April 2024 and shares will be allotted at the above latest published B share NAV.

This announcement contains inside information as stipulated under the UK version of the Market Abuse Regulation No 596/2014 which is part of English law by virtue of the European (Withdrawal) Act 2018, as amended. On publication of this announcement via a regulatory information service, this information is considered to be in the public domain.

For further information, please contact:

John Hustler, Seneca Growth Capital VCT Plc at john.hustler@btconnect.com

Richard Manley, Seneca Growth Capital VCT Plc at Richard.Manley@senecapartners.co.uk

Any enquiries regarding the offer for subscription of B shares should be directed to:

Matt Currie at Seneca Partners Limited on 01942 295 981 or at Matt.Currie@senecapartners.co.uk

Date   Source Headline
25th Mar 202210:00 amGNWIssue of Supplementary Prospectus
25th Mar 20227:01 amGNWNAV Update
25th Mar 20227:00 amGNWFinal Results for the Year Ended 31 December 2021
8th Mar 20227:00 amGNWInterim Dividend on B Shares
10th Dec 202111:40 amGNWDirector/PDMR Shareholding
8th Dec 20213:24 pmGNWIssue of Equity and Total Voting Rights
16th Nov 20217:00 amGNWSecond Interim Dividend on B Shares
29th Oct 202111:42 amGNWOffer for Subscription and Publication of Prospectus
28th Oct 20211:06 pmGNWTR-1: Notification of major holdings
21st Oct 20219:01 amGNWNAV Update
16th Sep 202112:16 pmRNSSecond Price Monitoring Extn
16th Sep 202112:14 pmRNSPrice Monitoring Extension
14th Sep 20212:07 pmRNSSecond Price Monitoring Extn
14th Sep 20212:01 pmRNSPrice Monitoring Extension
25th Aug 20214:41 pmRNSSecond Price Monitoring Extn
25th Aug 20214:36 pmRNSPrice Monitoring Extension
12th Aug 20214:42 pmRNSSecond Price Monitoring Extn
12th Aug 20214:38 pmRNSPrice Monitoring Extension
26th Jul 20217:00 amGNWHalf-year report
15th Jun 202112:18 pmGNWIssue of Equity and Total Voting Rights
15th Jun 20217:00 amGNWB Share Net Asset Value
3rd Jun 202110:51 amGNWInterim Capital Dividend on Ordinary Shares
20th May 20217:00 amGNWB Share Extension of Offer
28th Apr 202110:52 amGNWIssue of Equity and Total Voting Rights
1st Apr 20215:29 pmGNWDirector/PDMR Shareholding
1st Apr 202111:36 amGNWIssue of Equity and TVR
31st Mar 20217:00 amGNWNet Asset Value(s)
29th Mar 20215:12 pmGNWResult of AGM
4th Mar 20215:26 pmGNWDirector/PDMR Shareholding
2nd Mar 202112:50 pmGNWIssue of Equity and Total Voting Rights
24th Feb 20211:49 pmGNWIssue of Prospectus
23rd Feb 20217:00 amGNWFinal Results and NAV Update
18th Feb 20217:00 amGNWDividend Declaration
10th Dec 20203:57 pmGNWDirector/PDMR Shareholding
9th Dec 20203:49 pmGNWIssue of Equity and Total Voting Rights
5th Nov 20207:00 amGNWDividend Declaration
13th Oct 20204:22 pmGNWOffer for Subscription
5th Oct 20207:00 amGNWSecond Interim Capital Dividend
5th Oct 20207:00 amGNWNAV Update
16th Sep 20207:00 amGNWInvestment Realisations and NAV
21st Aug 202010:55 amGNWChange of Registered Office
30th Jul 20207:00 amGNWHalf-year report
10th Jul 202011:43 amGNWIssue of Equity
24th Jun 202012:35 pmGNWB Share - Extension of Offer
13th May 20203:03 pmGNWPublication of a supplementary prospectus
29th Apr 202012:45 pmGNWIssue of Equity
29th Apr 20207:00 amGNWResult of Annual General Meeting
27th Apr 20206:52 pmGNWUpdate on Omega, Optibiotix and NAVs
20th Apr 20206:36 pmGNWOmega Diagnostics, Net Asset Value, New B Share Pool Investments
7th Apr 20204:35 pmGNWIssue of Supplementary Prospectus

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.